Organovo entered into a Research Collaboration Agreement with L’Oreal USA Products, agreeing to collaborate on the development of skin tissue models utilizing the Organovo's proprietary NovoGen Bioprinting Platform and skin cell technology developed by L’Oreal. 

Under the Agreement, L’Oreal will have the exclusive right to use the skin tissue models for the development, manufacturing, testing, evaluation and sale of non-prescription cosmetic, beauty, dermatology and skin care products and nutraceutical supplements. The Company retained the right to use the skin tissue models for toxicity and efficacy testing of prescription drugs and for developing and testing surgically transplanted and therapeutic tissues.